UT-MD Anderson Cancer Center: Targeting Menin Induces Responses in Acute Leukemias With KMT2A Rearrangements or NPM1 Mutations
March 16, 2023
March 16, 2023
HOUSTON, Texas, March 16 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
The overall response rate amon . . .
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
The overall response rate amon . . .